Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
87.9M
-
Shares change
-
-9.86M
-
Total reported value, excl. options
-
$149M
-
Value change
-
-$9.35M
-
Put/Call ratio
-
0.2
-
Number of buys
-
40
-
Number of sells
-
-66
-
Price
-
$1.69
Significant Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q3 2025
150 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common shares as of Q3 2025.
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87.9M shares
of 250M outstanding shares and own 35.11% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (49.6M shares), VANGUARD GROUP INC (9.01M shares), RAFFLES ASSOCIATES LP (5.39M shares), COMERICA BANK (4.6M shares), MILLENNIUM MANAGEMENT LLC (2.68M shares), GEODE CAPITAL MANAGEMENT, LLC (2.42M shares), BlackRock, Inc. (2.23M shares), RENAISSANCE TECHNOLOGIES LLC (1.91M shares), Dauntless Investment Group, LLC (1.61M shares), and MORGAN STANLEY (1.01M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.